Drug
Afuresertib clinical trials
Also written GSK2110183.
- studies test it
- 14
- open now
- 0
- in phase 3
- 1
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2011 | 4 |
| 2012 | 2 |
| 2014 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
Laekna Limited (4) · GlaxoSmithKline (4) · Novartis Pharmaceuticals (3) · Novartis (2) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Lapiteronel (1) · Prednisone (1) · Ofatumumab (1) · Bortezomib (1) · Dexamethasone (1) · Immediate-release Tablet Afuresertib (1) · Trametinib (1) · Paclitaxel (1)
Studies
Open first, then newest update. How each study uses afuresertib is read from its arms, and is right about nine times in ten.
Testing it · 14
- Study With Afuresertib and Paclitaxel in Platinum Resistant OvarianCompletedPhase 2Laekna LimitedNCT04374630Written as Afuresertib
- Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerActive, not recruitingPhase 3Laekna LimitedNCT04851613Written as Afuresertib
- Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPCCompletedPhase 1/2Laekna LimitedNCT04060394Written as Phase I and Phase II: LAE001/prednisone + afuresertib
- Human Mass Balance and Biotransformation Study of [14C]AfuresertibCompletedPhase 1Laekna LimitedNCT05489744Written as [14C]Afuresertib
- Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma PatientsTerminatedPhase 1Novartis PharmaceuticalsNCT02177682Written as Afuresertib
- A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell HistiocytosisCompletedPhase 2GlaxoSmithKlineNCT01395004Written as GSK2110183
- An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2University Health Network, TorontoNCT01532700Written as Ofatumumab with GSK2110183
- Continuation Study of the Oral AKT Inhibitor GSK2110183CompletedPhase 2Novartis PharmaceuticalsNCT01531894Written as GSK2110183 (afuresertib)
- Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple MyelomaCompletedPhase 1NovartisNCT01428492Written as GSK2110183
- Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of AfuresertibCompletedPhase 1GlaxoSmithKlineNCT02040480Written as GSK2110183 Gelatin Capsule
- A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor CancersCompletedPhase 1GlaxoSmithKlineNCT01476137Written as GSK2110183
- Study of Afuresertib Combined With Paclitaxel in Gastric CancerCompletedPhase 1Novartis PharmaceuticalsNCT02240212Written as Afuresertib
- A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)TerminatedPhase 1NovartisNCT02235740Written as Afuresertib
- A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple MyelomaWithdrawnPhase 2GlaxoSmithKlineNCT01445587Written as Part 1; Cohort 1
Given in every arm · 2 — afuresertib is usual care beside what is tested
- Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1CompletedPhase 1/2Laekna LimitedNCT05383482Written as Afuresertib
- Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or AibrateroneWithdrawnPhase 1GlaxoSmithKlineNCT02380313Written as Afuresertib
Codes
What other systems call afuresertib · ClinicalTrials.gg INT000123
- MeSH (NLM) C000593263afuresertibOne source NLM
- UNII (FDA) 8739X25QI3AFURESERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27074327afuresertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82390AfuresertibOne source FDA
- DrugBank DB11648One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000593263 | afuresertib | One source NLM |
| UNII (FDA) | 8739X25QI3 | AFURESERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074327 | afuresertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82390 | Afuresertib | One source FDA |
| DrugBank | DB11648 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.